Guggenheim Reiterates Buy Rating for Compass Therapeutics (NASDAQ:CMPX)
Guggenheim restated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report issued on Wednesday morning,Benzinga reports. They currently have a $12.00 target price on the stock. A number of other research analysts also recently commented on the stock. Jefferies Financial Group lifted their price objective on shares of Compass […]
Guggenheim restated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report issued on Wednesday morning,Benzinga reports. They currently have a $12.00 target price on the stock. A number of other research analysts also recently commented on the stock. Jefferies Financial Group lifted their price objective on shares of Compass […]
